Navigation Links
Cardium's InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
Date:6/19/2008

ational sales organizations."

"We look forward to marketing InnerCool's products in Italy and are pleased to offer a comprehensive portfolio of temperature modulation systems to Italy's physicians and healthcare providers in this growing therapeutic market," stated Paolo Cremascoli, Chief Executive Officer of N.G.C. Medical. "The InnerCool product line is a good fit for our team since key clinicians and areas of the hospital where we focus are utilizing temperature modulation products and therapies."

InnerCool's Surface and Endovascular Temperature Modulation Systems

InnerCool's new CoolBlue(TM) surface temperature modulation system, which includes a console and a disposable CoolBlue vest with upper thigh pads, is designed to provide a tool for use in less acute patients or in clinical settings best suited to prolonged temperature management. InnerCool's CoolBlue vest and thigh pads wrap the body without requiring any adhesives to stick to the skin and produce cooling rates of around 1 degree Celsius per hour, i.e. similar to those of currently-marketed surface cooling systems and endovascular systems using inflatable balloon-based catheters. InnerCool's CoolBlue external or surface-based temperature modulation system is designed to cool or warm patients from outside of their bodies and is intended for use in less acute settings such as in-hospital fever management.

InnerCool's endovascular approach to patient temperature modulation is based on a single-use flexible metallic catheter and a fully-integrated cooling system, which allows for rapid and controlled cooling and re-warming. InnerCool's endovascular system integrates a number of desirable features including a slim catheter profile, a highly efficient flexible metallic thermal transfer element, a built-in temperature monitoring sensor, and a programmable console capable of rapidly and controllably inducing, maintaining and reversing therapeutic cooling. InnerCool's endovascular cat
'/>"/>

SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
2. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
3. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
4. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
5. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
6. Fate Therapeutics Created by Leading Stem Cell Scientists to Pursue New Approaches to Stem Cell Therapies
7. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
8. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
9. Pipeline for Lung Cancer Therapies is Focus of New MedPredict Report
10. Teva Pharmaceuticals Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis
11. CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 2015  CytRx Corporation (NASDAQ: CYTR ), ... oncology, today announced positive updated results from its ... the treatment of unresectable glioblastoma multiforme (GBM), a ... trial is designed to investigate the preliminary efficacy ... have progressed following prior treatment with surgery, radiation ...
(Date:5/21/2015)... Tunnell Consulting, Inc. today ... senior statistician and Principal, a position to which she ... management and analysis of complex and large data sets ... “We’re delighted to have Julia join the Tunnell team ... Dr. Philippe Cini, Group Vice President and leader of ...
(Date:5/20/2015)... Pa. , May 20, 2015  Select ... that the Federal Trade Commission granted early termination ... Antitrust Improvements Act of 1976, as amended, applicable ... MJ Acquisition Corporation, a joint venture that Select ... L.P. As previously announced, MJ Acquisition ...
(Date:5/20/2015)... May 20, 2015  Haemonetics Corporation (NYSE: HAE ... & CEO, will present at The Jefferies 2015 Global ... on June 1 st , 2015 at 8:30am Eastern ... Concannon,s presentation live via webcast at: http://wsw.com/webcast/jeff88/hae ... HAE ) is a global healthcare company dedicated ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2
... announced today that they have entered into a strategic ... at Roche,s global research sites. BioDuro will provide research ... which can help to shorten (internal) drug discovery timelines. ... relationship.Roche has many years of experience in partnering with ...
... hemophilia in miceGAITHERSBURG, Md., April 6 VIRxSYS Corporation ... " Trans -splicing into Highly Abundant Albumin Transcripts for Production ... journal Molecular Therapy . The study describes a novel ... is inserted into the albumin gene "hijacks" the albumin, causing ...
... April 6 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: ... Stern, has posted a new entry on his blog ... company,s recent meetings in Zurich, Switzerland, further development plans ... plans for clinical-grade Oxycyte, and plans for raising additional ...
Cached Biology Technology:BioDuro and Roche Expand Strategic Collaboration to Provide Drug Discovery Services 2VIRxSYS Publishes New Study on RNA Therapy 2
(Date:5/20/2015)... May 20, 2015 NXT-ID, Inc. (NASDAQ: ... wholly owned subsidiary, 3D-ID LLC, a company engaged in ... for the biometrics technology portion of the recently awarded ... the Department of the Army. 3D-ID LLC ... for government, law enforcement and security agencies. ...
(Date:5/19/2015)... YORK , May 19, 2015  Technology is ... both internally and in the cloud. Passwords and their ... use of OTP and standards-based specifications such as those ... the outmoded use of passwords presents for BYOD, COPE, ... a unified biometric identity protocol. In ...
(Date:5/18/2015)... May 18, 2015 Fingerprint Cards (FPC) ... FPC1025, FPC1145, FPC1155 and FPC1035 from one if its module ... and including Q3 2015 and the sensors will be used ... order values for 2015 hereby amount to 740 MSEK to ... of 140 MSEK and a number of smaller orders not ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... the University of Leeds, has found that a common ... monoxide poisoning. Animal studies have shown that the ... deaths from arrhythmias irregular or abnormally paced heartbeats ... The findings could have important implications for the development ...
... August 6, 2012 Individuals with mutations in BRCA1 and ... and ovarian cancers. Families at risk have been seeking ... but the standard method of direct sequencing is labor-intensive, costly, ... BRCA2 genes. A group of Canadian scientists has developed ...
... is able to source food from the land as well as ... University of London has found. Scientists analysed the behaviour of ... the water level of the lake was low, the crayfish found ... journal PLoS ONE today (3 August 2012). Lead ...
Cached Biology News:Anti-angina drug shows protective effects from carbon monoxide 2Anti-angina drug shows protective effects from carbon monoxide 3New method provides fast, accurate, low cost analysis of BRCA gene mutations in breast cancer 2Crayfish species proves to be the ultimate survivor 2